Based on 1 Wall Street analysts offering 12 month price targets for Homology Medicines in the last 3 months. The average price target is $1.50 with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 169.40% change from the last price of $0.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2023","12":"Dec<br/>2023","25":"Dec<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.6138461538461539,0.6876923076923077,0.7615384615384615,0.8353846153846154,0.9092307692307693,0.9830769230769231,1.0569230769230769,1.1307692307692307,1.2046153846153846,1.2784615384615385,1.3523076923076922,1.426153846153846,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.6138461538461539,0.6876923076923077,0.7615384615384615,0.8353846153846154,0.9092307692307693,0.9830769230769231,1.0569230769230769,1.1307692307692307,1.2046153846153846,1.2784615384615385,1.3523076923076922,1.426153846153846,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.6138461538461539,0.6876923076923077,0.7615384615384615,0.8353846153846154,0.9092307692307693,0.9830769230769231,1.0569230769230769,1.1307692307692307,1.2046153846153846,1.2784615384615385,1.3523076923076922,1.426153846153846,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.38,"date":1670544000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1672963200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1675382400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1693526400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1696550400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1698969600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1.50

Average Price Target$1.50

Lowest Price Target$1.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Robert W. Baird

xxxxxxxxxxxxx

Reiterated

11/16/23

Richard Law CFA

Credit Suisse

$1.70

Hold

205.32%

Upside

Reiterated

08/15/23

Homology Medicines (FIXX) PT Lowered to $1.70 at Credit SuisseCredit Suisse analyst Richard Law lowered the price target on Homology Medicines (NASDAQ: FIXX) to $1.70 (from $2.00) while maintaining a Neutral rating.

Matthew Biegler

Oppenheimer

―

Hold

―

Assigned

07/31/23

Patrick Trucchio

H.C. Wainwright

$20.00

Buy

3491.95%

Upside

Reiterated

05/15/23

H.C. Wainwright Sticks to Their Buy Rating for Homology Medicines (FIXX)

Matthew Barcus

Chardan Capital

$7.00

Buy

1157.18%

Upside

Reiterated

05/11/23

Homology Medicines price target lowered to $7 from $8 at ChardanHomology Medicines price target lowered to $7 from $8 at Chardan

Luca Issi

RBC Capital

$3.00

Hold

438.79%

Upside

Reiterated

05/11/23

Homology Medicines (FIXX) Gets a Hold from RBC Capital

Michelle Gilson

Canaccord Genuity

$7.00

Buy

1157.18%

Upside

Reiterated

04/06/23

Homology Medicines price target lowered to $7 from $19 at CanaccordHomology Medicines price target lowered to $7 from $19 at Canaccord

Thomas Shrader

BTIG

$12.00

Buy

2055.17%

Upside

Reiterated

04/03/23

BTIG Sticks to Its Buy Rating for Homology Medicines (FIXX)

Dae Gon Ha

Stifel Nicolaus

$2.00

Hold

259.20%

Upside

Reiterated

03/13/23

Homology Medicines (FIXX) Gets a Hold from Stifel Nicolaus

Best Analysts Covering Homology Medicines

Which Analyst Should I Follow If I Want to Buy FIXX and Sell After:

1 Month

Patrick TrucchioH.C. Wainwright

Success Rate

6/14 ratings generated profit

Average Return

-3.21%

reiterated a buy rating 7 months ago

Copying Patrick Trucchio's trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of -3.21% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Michelle GilsonCanaccord Genuity

Success Rate

2/9 ratings generated profit

Average Return

-12.86%

reiterated a buy rating 8 months ago

Copying Michelle Gilson's trades and holding each position for 3 Months would result in 22.22% of your transactions generating a profit, with an average return of -12.86% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Michelle GilsonCanaccord Genuity

Success Rate

0/9 ratings generated profit

Average Return

-44.51%

reiterated a buy rating 8 months ago

Copying Michelle Gilson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -44.51% per trade.

2 Years

Michelle GilsonCanaccord Genuity

Success Rate

0/9 ratings generated profit

Average Return

-71.58%

reiterated a buy rating 8 months ago

Copying Michelle Gilson's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -71.58% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

FIXX Financial Forecast

FIXX Earnings Forecast

Next quarter’s earnings estimate for FIXX is -$0.28 with a range of -$0.30 to -$0.27. The previous quarter’s EPS was -$0.57. FIXX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.72% of the time in the same period. In the last calendar year FIXX has Underperformed its overall industry.

FIXX Sales Forecast

Next quarter’s sales forecast for FIXX is $500.00K with a range of $500.00K to $500.00K. The previous quarter’s sales results were $0.00. FIXX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.30% of the time in the same period. In the last calendar year FIXX has Underperformed its overall industry.

FIXX Analyst Recommendation Trends

In the current month, FIXX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The FIXX average analyst price target in the past 3 months is $1.50

FIXX Stock Forecast FAQ

What is FIXX’s average 12-month price target, according to analysts?

Based on analyst ratings, Homology Medicines Inc’s 12-month average price target is $1.50.

What is FIXX’s upside potential, based on the analysts’ average price target?

Homology Medicines Inc has 169.40% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FIXX a Buy, Sell or Hold?

Homology Medicines Inc has a conensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Homology Medicines Inc’s price target?

The average price target for Homology Medicines Inc is $1.50. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1.50 ,the lowest forecast is $1.50. The average price target represents 169.40% Increase from the current price of $0.557.

What do analysts say about Homology Medicines Inc?

Homology Medicines Inc’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of FIXX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Homology Medicines (FIXX) Stock Forecast & Price Target

FIXX Analyst Ratings

FIXX Stock 12 Months Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Homology Medicines

FIXX Financial Forecast

FIXX Earnings Forecast

FIXX Sales Forecast

FIXX Analyst Recommendation Trends

FIXX Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts